Vanguard Group Inc. Decreases Stock Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Vanguard Group Inc. trimmed its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 3.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 6,705,633 shares of the company’s stock after selling 262,667 shares during the quarter. Vanguard Group Inc.’s holdings in MiMedx Group were worth $64,508,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. IMG Wealth Management Inc. bought a new position in MiMedx Group during the 4th quarter valued at about $28,000. Van ECK Associates Corp purchased a new position in shares of MiMedx Group during the fourth quarter valued at approximately $40,000. SkyView Investment Advisors LLC grew its stake in shares of MiMedx Group by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock valued at $77,000 after buying an additional 3,000 shares during the last quarter. AlphaQuest LLC purchased a new stake in shares of MiMedx Group in the fourth quarter worth approximately $88,000. Finally, Savant Capital LLC bought a new stake in shares of MiMedx Group during the 4th quarter worth approximately $100,000. Institutional investors own 79.15% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th. StockNews.com raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 4th.

MiMedx Group Trading Down 4.2 %

Shares of NASDAQ MDXG opened at $6.86 on Friday. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14. The firm has a market cap of $1.01 billion, a PE ratio of 12.47 and a beta of 1.74. The business has a fifty day simple moving average of $7.89 and a two-hundred day simple moving average of $7.98. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The firm had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. Analysts expect that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Kimberly Maersk-Moller sold 4,106 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the sale, the insider now owns 310,836 shares of the company’s stock, valued at $2,452,496.04. This trade represents a 1.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO William Frank Iv Hulse sold 54,596 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the completion of the transaction, the chief accounting officer now owns 440,178 shares of the company’s stock, valued at $3,473,004.42. This represents a 11.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 144,018 shares of company stock worth $1,130,312. Corporate insiders own 1.30% of the company’s stock.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.